Celldex Therapeutics, Inc. (CLDX) - Stock Analysis
Last updated: Jun 14, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Completion of enrollment in two global Phase 3 EMBARQ-CSU trials and multiple Phase 2 data presentations at AAAAI (Feb 27âMar 2) have ignited a ~35% short-term rally; near-term scientific disclosures can drive further spikes, making CLDX a tactically attractive, event-driven biotech trade.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Net Cash ⢠Heavy Burn ⢠Tiny Revenue CLDX is highly liquid and lightly leveraged, but persistent losses, negative cash flow, and minimal revenue make its valuation look stretched on current fundamentals. #cash-richâ #high-burnâ
Price Behavior
Key Price Behavior Insights: ⢠Range-bound base ⢠Resistance test ⢠Support hold Support Level: $28.60 Resistance Level: $31.60-$31.70 Over the last month, CLDX has been range-bound but bounced sharply from the $28.6 area to reclaim $30â$31, yet it still needs a decisive break above $31.6â$31.7 to confirm a durable bullish reversal.
Sentiment & News
Key News Insights: ⢠EAACI Showcase ⢠Barzolvolimab Data ⢠CDX-622 Poster Celldex will spotlight barzolvolimab and CDX-622 clinical updates at the 2026 EAACI Congress, underscoring continued progress across its allergy-focused mast cell pipeline.
AI Summary
CLDX should now be viewed less as a near-term solvency story and more as a cash-backed, catalyst-driven biotech where barzolvolimab must prove clear differentiation in mast-cell disease to justify the valuation, with the main risk being that clinical updates remain incremental rather than truly de-risking; the strong runway buys time, but not proof.
Description
Celldex Therapeutics is a biopharmaceutical company developing monoclonal and bispecific antibody therapies for inflammatory conditions and various cancers. Its clinical pipeline includes programs directed at KIT, CD40 and a bispecific combining PD-L1 blockade with CD27 costimulation, among other antibody candidates. The company maintains research and licensing relationships with academic institutions and Amgen, and is headquartered in Hampton, New Jersey, having been incorporated in 1983.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 26 | Mar 5 | CLDX | Celldex Therapeutics, Inc. | Completion of enrollment in two global Phase 3 EMBARQ-CSU trials and multiple Phase 2 data presentations at AAAAI (Feb 27âMar 2) have ignited a ~35% short-term rally; near-term scientific disclosures can drive further spikes, making CLDX a tactically attractive, event-driven biotech trade. | Closed | -4.2% |